Proactive Investors - Run By Investors For Investors

Medlab Clinical signs deal to launch its nutraceuticals in Priceline Pharmacy

Along with Priceline, more than 2100 independent pharmacies will also be able to access Medlab’s nutraceutical range.
Priceline Pharmacy
The cannabis drug developer aims to help patients with diagnosed chronic diseases

Medlab Clinical Ltd (ASX:MDC) has signed an agreement with Australian Pharmaceutical Industries (API) to range Medlab’s nutraceuticals in Priceline Pharmacy, one of Australia’s biggest pharmacy groups.

As part of the agreement, API will also hold Medlab products in its warehouses, significantly expanding potential distribution to more than 2100 independent pharmacies who will now be able to easily access the product range.

READ: Medlab Clinical takes EMA and FDA approval track as cannabis research continues

The agreement positions Medlab’s nutraceutical range into professional pharmacy with onboarding expected to take 3-4 months.

It is anticipated these agreements will result in a substantial increase in sales in the 12-month period from official launch.

 

Medlab’s nutraceutical offering differs from general retail due to its exposure to clinical research and patents.

The company currently has 27 patents covering a large number of products in the nutraceutical range.

Included within the range are NanoCelle™ products which were developed using Medlab’s patented delivery platform.

READ: Medlab Clinical eyes cost savings following receipt of SME status in Europe

Medlab chief executive officer Dr Sean Hall said: “Medlab is very excited with this opportunity to work with Priceline Pharmacy and other independent groups as it allows us to support people in the community suffering chronic illnesses by providing them easier access to scientifically backed products via professional pharmacy.”

Medlab is expected to exhibit at this year’s largest pharmacy conference, APP on the Gold Coast in March.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

Sydney Harbour Bridge
January 23 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
cannabis bud on tray
April 25 2019
Armed with a new partnership with Canada's largest pharmacy and an international cultivator, Flowr is aiming to provide medicinal and recreational consumers around the world with premium, high-quality cannabis
RYAH vaporizer and cartridges
May 16 2019
RYAH is the first cannabis vaporizer that lets users precisely regulate dose and temperature

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use